Endmet Dosage/Direction for Use

Leuprorelin acetate must be administered under the supervision of a physician.
Endometriosis: The recommended duration of treatment with leuprorelin acetate alone or in combination with norethindrone acetate is six months. The choice of leuprolide acetate alone or leuprorelin acetate plus norethindrone acetate therapy for initial management of the symptoms and signs of endometriosis should be made by the health care professional in consultation with the patient and should take into consideration the risks and benefits of the addition of norethindrone to leuprorelin acetate alone.
If the symptoms of endometriosis recur after a course of therapy, retreatment with a six-month course of leuprorelin acetate monthly and norethindrone acetate 5 mg daily may be considered. Retreatment beyond this one six-month course cannot be recommended. It is recommended that bone density be assessed before retreatment begins to ensure that values are within normal limits. Leuprorelin acetate alone is not recommended for retreatment. If norethindrone acetate is contraindicated for the individual patient, then retreatment is not recommended.
An assessment of cardiovascular risk and management of risk factors such as cigarette smoking is recommended before beginning treatment with leuprorelin acetate and norethindrone acetate.
Uterine leiomyomata (fibroids): Recommended duration of therapy with leuprorelin acetate is up to 3 months. The symptoms associated with uterine leiomyomata will recur following discontinuation of therapy. If additional treatment with leuprorelin acetate is contemplated, bone density should be assessed prior to initiation of therapy to ensure that values are within normal limits.
The recommended dose of leuprorelin acetate , incorporated in a depot formulation. The lyophilized microspheres are to be reconstituted and administered monthly as a single intramuscular injection.